Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advertising Enforcers Have Little Patience For "Well Tolerated" Drug Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Term is too vague for promotional use, regulators say, but it is not always cited as a violation, even when other aspects of the advertisement are.
Advertisement

Related Content

DDMAC Slamming The Door On Open-Label Studies In Promotions
DDMAC Slamming The Door On Open-Label Studies In Promotions
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
Healthiness Of Actors In DTC Spots Returns As Issue As FDA Cites Aricept Ads
Dyax Kalbitor Is Third To Market For HAE, But First For All Acute Attacks
ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition
ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition

Topics

Advertisement
UsernamePublicRestriction

Register

PS071326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel